AKT1 is altered in 1.89% of malignant solid tumor patients [3].

AKT1 is an inclusion criterion in 27 clinical trials for malignant solid tumor, of which 21 are open and 6 are closed. Of the trials that contain AKT1 status and malignant solid tumor as inclusion criteria, 12 are phase 1 (7 open), 3 are phase 1/phase 2 (3 open), and 12 are phase 2 (11 open) [4].

AKT1 is altered in 4.96% of breast carcinoma patients [3].

AKT1 is an inclusion criterion in 10 clinical trials for breast carcinoma, of which 9 are open and 1 is closed. Of the trials that contain AKT1 status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 1/phase 2 (2 open), and 4 are phase 2 (4 open) [4].

AKT1 is altered in 0.91% of non-small cell lung carcinoma patients [3].

AKT1 is an inclusion criterion in 6 clinical trials for non-small cell lung carcinoma, of which 5 are open and 1 is closed. Of the trials that contain AKT1 status and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 4 are phase 2 (3 open) [4].

AKT1 is altered in 1.73% of colorectal carcinoma patients [3].

AKT1 is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain AKT1 status and colorectal carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

AKT1 is altered in 1.26% of melanoma patients [3].

AKT1 is an inclusion criterion in 3 clinical trials for melanoma, of which 3 are open and 0 are closed. Of the trials that contain AKT1 status and melanoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

AKT1 is altered in 1.36% of head and neck squamous cell carcinoma patients [3].

AKT1 is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain AKT1 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (1 open) [4].

AKT1 is altered in 1.43% of non-hodgkin lymphoma patients [3].

AKT1 is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain AKT1 status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [4].

AKT1 is altered in 4.94% of endometrial carcinoma patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

AKT1 is altered in 1.9% of prostate carcinoma patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for prostate carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and prostate carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 3 (1 open) [4].

AKT1 is altered in 1.8% of cancer patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain AKT1 status and cancer as inclusion criteria, 1 is early phase 1 (0 open) and 1 is phase 1 (1 open) [4].

AKT1 is altered in 1.33% of gastric adenocarcinoma patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for gastric adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain AKT1 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open) [4].

AKT1 is altered in 1.32% of small cell lung carcinoma patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

AKT1 is altered in 1.19% of ovarian carcinoma patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

AKT1 is altered in 1.31% of squamous cell lung carcinoma patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

AKT1 is altered in 0.59% of renal cell carcinoma patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

AKT1 is altered in 0.59% of pancreatic carcinoma patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

AKT1 is altered in 0.23% of hepatocellular carcinoma patients [3].

AKT1 is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain AKT1 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

AKT1 is altered in 5.01% of breast adenocarcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for breast adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and breast adenocarcinoma as inclusion criteria, 1 is phase 3 (1 open) [4].

AKT1 is altered in 3.87% of malignant uterine neoplasm patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 3.03% of thymic carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 2.05% of urothelial carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT1 is altered in 1.65% of cervical carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 2.03% of bladder carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 2.02% of liposarcoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT1 is altered in 1.85% of oropharyngeal squamous cell carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for oropharyngeal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and oropharyngeal squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT1 is altered in 2.19% of undifferentiated pleomorphic sarcoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT1 is altered in 1.43% of gallbladder carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 1.1% of thyroid gland carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT1 is altered in 1.06% of osteosarcoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT1 is altered in 0.75% of histiocytic and dendritic cell neoplasm patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 1.13% of head and neck carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 1.4% of soft tissue sarcoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 1.45% of B-cell non-hodgkin lymphoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 0.93% of lung carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 0.56% of adenocarcinoma of the gastroesophageal junction patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 1.02% of hematologic and lymphocytic disorder patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT1 is altered in 0.37% of bile duct carcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 0.37% of cholangiocarcinoma patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is altered in 0.59% of hematopoietic and lymphoid malignancy patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT1 is altered in 0.55% of hematopoietic and lymphoid system neoplasm patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT1 is altered in 0.28% of myelodysplastic syndromes patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT1 is altered in 0.06% of myeloid neoplasm patients [3].

AKT1 is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT1 is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT1 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT1 is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT1 is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT1 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT1 is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT1 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

AKT1 is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

AKT1 is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [4].

AKT1 is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [4].